Significant Accounting Polices - Additional Information (Details) - USD ($)					3 Months Ended			9 Months Ended
	Oct. 12, 2021	Oct. 06, 2021	Mar. 19, 2021	Jan. 25, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Oct. 04, 2021	Dec. 31, 2020
Schedule Of Significant Accounting Policies [Line Items]
Upfront nonrefundable payment				$ 1,000,000.0
Loan in principal amount				$ 4,000,000.0
Issuance and bore interest rate				6.00%
Reimbursement payment			$ 14,000,000.0
Collaboration agreement amount			25,000,000.0
Development payments			10,000,000.0
Deferred collaboration funding					$ 17,771,957			$ 17,771,957
Income tax expense (benefit)					$ 0		$ 0	$ 0	$ 0
Accounting Standard Update [Extensible List]								ASU No. 2020-06
Change in accounting principle, accounting standards update, adopted					true			true
Change in accounting principle, accounting standards update, adoption date					Mar. 31, 2021			Mar. 31, 2021
Change in accounting principle, accounting standards update, immaterial effect					true			true
Accounts Payable and Accrued Expenses
Schedule Of Significant Accounting Policies [Line Items]
Preclinical or clinical study expense					$ 0			$ 0			$ 1,800,000
Cash and Cash Equivalents
Schedule Of Significant Accounting Policies [Line Items]
Investments in money market funds					12,900,000			12,900,000			$ 5,300,000
Performance Obligations
Schedule Of Significant Accounting Policies [Line Items]
Deferred collaboration funding					17,800,000			17,800,000
Deferred collaboration funding, cash received					$ 25,000,000.0			25,000,000.0
Revenue recognized								900,000
Offset to research and development expenses								4,800,000
Offset to general and administrative expenses								1,600,000
Relief
Schedule Of Significant Accounting Policies [Line Items]
Non-cash reduction recognized in secured loan								$ 4,000,000.0
Collaboration Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received			10,000,000.0	$ 10,000,000.0
Reimbursement payment			14,000,000.0	14,000,000.0
Repayment of outstanding balance of prior loan and interest			4,000,000.0	$ 4,000,000.0
Development and commercial launch costs			$ 20,000,000.0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty net sales received			15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Percentage of development and commercialization services			60.00%
Percentage of payment net profit territory			60.00%
Upfront non-refundable payment received				$ 1,000,000.0
Collaboration Agreement | Relief | First Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received						$ 10,000,000.0
Collaboration Agreement | Relief | Second Development Payment | Subsequent Event
Schedule Of Significant Accounting Policies [Line Items]
Potential proceeds from development payments subject to new drug application										$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0
Waiver and Agreement | Relief | Second Development Payment | Subsequent Event
Schedule Of Significant Accounting Policies [Line Items]
Potential proceeds from second tranche of development payments subject to new drug application		$ 5,000,000.0
Second tranche of development payment, expiry date		Jan. 14, 2022
Written notice period (in business days) for second tranche of development payment		15 days
Collaboration And License Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received			$ 1,000,000.0